Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Signs of myopathy detected before muscle formation


An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself
muscle fiber muscle fiber

Virginie Mournetas* and the Muscular Diseases team headed by Christian Pinset at I-Stem (Inserm UMR 861, AFM-Téléthon) have shown that molecular dysregulations associated with Duchenne muscular dystrophy appear during embryonic development before muscle tissues even start to develop. The combination of an in vitro cellular model of muscle formation created from pluripotent stem cells and a multiomic approach enabled this discovery.

Duchenne muscular dystrophy (DMD) is a rare genetic disease occurring in roughly 1 out of 5000 male births and causing progressive muscle degeneration. The disease is usually diagnosed around the age of four, when muscle damage has already become significant. The efficacy of certain treatments may be hampered by this belated diagnosis, which is particularly regrettable given that current findings, some born of research at I-Stem, suggest that the disease may appear before birth. Indeed, one of the laboratory’s objectives is to better identify the moment at which the disease begins to manifest.

 

The I-Stem Muscular Diseases team designed an original study on DMD onset involving a protocol to guide iPS cell differentiation toward the muscle cell phenotype. Their protocol faithfully reproduced the key steps in myogenesis, (i.e., the formation of skeletal muscle during embryonic development): first the formation of the mesoderm, then the somites (an intermediate structure) and through to the development of myotubes (see photo), a precursor to muscle fibers. They used the protocol on iPS cells derived from either healthy people or diseased patients. Multiomics analyses (transcriptomics, microRNA, proteomics) were done at five time intervals during the 25 days of myotube differentiation to determine molecular activity in the healthy or pathological cells.

 

As early as the somite stage, 10% of the pathological transcriptomes (indicating the genes expressed by the cells) showed dysregulations compared to the healthy transcriptomes. Notably, those dysregulations concerned mitochondrial genes, known for their role in DMD.

 

This unprecedented study demonstrating a very early manifestation of DMD during embryonic development and even upstream of muscle formation itself suggests a need for a reappraisal of the disease’s natural history. Particularly, the defective dystrophin protein, which is highly deleterious to muscle fibers and the cause of DMD, could also have other effects. This aspect merits exploration as it may explain some non-muscular DMD symptoms. Toward that goal, all of the study’s analyses have been grouped in a database available to the scientific community.

  • Virginie Mournetas

    Virginie Mournetas had benefitted from a Fondagen/Genopole research grant for an initial postdoctoral project at I-Stem. That project preceded several others, including the one described here.

  • Induced Pluripotent Stem (iPS)

    Induced Pluripotent Stem (iPS) cells are created by collecting differentiated cells, those of the skin for example, and genetically reprogramming them back to the pluripotent state.

References

Journal of Cachexia, Sarcopenia and Muscle (2021)

Myogenesis modelled by human pluripotent stem cells: a multi‐omic study of Duchenne myopathy early onset. .
doi : 10.1002/jcsm.12665

Database

Designed by the research team, to access this link: https://muscle-dmd.omics.ovh/

Article posted on 10 June 2021

Share
Highlights

Latest news


l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

Discover
A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Discover
Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Discover
Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Discover
Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Discover
Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Discover
Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

Discover
Logos Istem & Généthon

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.

Discover
IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Discover
Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

Discover
CNRGH - Consequences of phthalate exposure during pregnancy

Consequences of phthalate exposure during pregnancy

Jörg Tost and his team of the National Center of Human Genomics Research (CNRGH; CEA) were part of a large collaborative study aimed at determining the genome-wide correlation between phthalate exposure during pregnancy and methylation of placental DNA.

Discover
INtegrare / Généthon - Efficacité à long terme de la thérapie génique d’un déficit immunitaire

Long-term efficacy for an immunodeficiency gene therapy

A gene therapy conceived by Genethon has been shown to confer long-term efficacy against Wiskott-Aldrich syndrome, an immune deficiency disorder.

Discover
I-Stem, IPSEN & LMN recreate the human muscle-nerve system

A cellular model to recreate the human muscle-nerve system

Researchers from I-Stem, IPSEN and LMN have conceived a cellular muscle-nerve model to test the therapeutic potential of botulinum toxins in vitro.

Discover
Genoscope - CNS - Genopole's laboratory

Filling the gaps in the banana’s genome

Des chercheurs de Genoscope en collaboration avec une équipe du Cirad sont parvenus à reconstituer la séquence intégrale de chromosomes de bananier.

Discover
traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.

Discover
SYSFATE

Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

Discover
Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

Discover
LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

Discover
NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Discover
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.

Discover
View all >
With the support from